Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $199.85, for a total transaction of $599,550.00. Following the transaction, the insider owned 150,023 shares of the company's stock, valued at approximately $29,982,096.55. The trade was a 1.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Solomon Moshkevich also recently made the following trade(s):
- On Tuesday, February 3rd, Solomon Moshkevich sold 1,639 shares of Natera stock. The stock was sold at an average price of $230.77, for a total transaction of $378,232.03.
- On Monday, February 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $231.44, for a total transaction of $694,320.00.
- On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The stock was sold at an average price of $237.66, for a total transaction of $285,192.00.
- On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The shares were sold at an average price of $240.53, for a total value of $243,656.89.
- On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $68,855.00.
- On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70.
- On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The shares were sold at an average price of $228.95, for a total value of $675,631.45.
- On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total value of $1,082,725.92.
Natera Stock Performance
Shares of NTRA opened at $207.04 on Wednesday. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The business has a 50-day moving average of $225.25 and a 200 day moving average of $204.78. The firm has a market cap of $29.34 billion, a P/E ratio of -135.32 and a beta of 1.65.
Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.81. The firm had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 16.71%. During the same quarter last year, the business earned ($0.41) earnings per share. As a group, research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have commented on NTRA shares. Wells Fargo & Company raised their target price on Natera from $205.00 to $215.00 and gave the stock an "equal weight" rating in a research note on Friday, February 27th. TD Cowen reissued a "buy" rating on shares of Natera in a report on Wednesday, January 7th. Piper Sandler boosted their price objective on shares of Natera from $220.00 to $230.00 and gave the company an "overweight" rating in a research note on Tuesday, November 11th. Zacks Research upgraded shares of Natera from a "strong sell" rating to a "hold" rating in a research note on Thursday, January 1st. Finally, Robert W. Baird raised their price target on shares of Natera from $239.00 to $257.00 and gave the company an "outperform" rating in a report on Friday, February 27th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $253.47.
Get Our Latest Stock Report on NTRA
Institutional Investors Weigh In On Natera
A number of institutional investors and hedge funds have recently bought and sold shares of NTRA. Integrated Wealth Concepts LLC lifted its position in Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company's stock valued at $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC raised its position in shares of Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company's stock valued at $644,000 after buying an additional 1,847 shares in the last quarter. Focus Partners Wealth lifted its holdings in shares of Natera by 8.6% during the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company's stock worth $847,000 after acquiring an additional 474 shares during the last quarter. Sivia Capital Partners LLC purchased a new position in Natera in the second quarter worth $298,000. Finally, Envestnet Asset Management Inc. increased its stake in Natera by 5.9% in the second quarter. Envestnet Asset Management Inc. now owns 172,022 shares of the medical research company's stock valued at $29,061,000 after acquiring an additional 9,651 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.
Natera Company Profile
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
